Schlieren-based biotech Mabylon, developing human-derived antibodies for allergies, has raised €31.8 million to advance its lead candidate MY006 and early-stage pipeline.
- Founded in 2015, Mabylon AG specializes in the discovery and development of human-derived, multi-specific antibodies to treat severe allergies, inflammation, and neurological disorders.
- Using a proprietary B-cell screening platform, Mabylon rapidly identifies natural antibodies from patients and immunized animals, enabling the creation of high-quality antibody libraries.
- These antibodies are cloned and expressed within weeks, then functionally tested and engineered to select the most promising therapeutic candidates.
- Mabylon’s approach focuses on leveraging the natural human immune response to target disease-relevant epitopes, particularly in allergy, to develop novel antibody therapeutics with high specificity and therapeutic potential.
Details of the deal
- The funding comes from Mabylon’s existing private investors, with a significant share provided by former Roche executives and board members.
“The funds will enable Mabylon to reach clinical proof-of-concept and further advance its early-stage pipeline. I would like to thank Prof. Adriano Aguzzi for his contributions to the board and welcome Thomas Hecht as a new board member," Chairman of Mabylon’s Board of Directors, Gottlieb Keller, stated.
- Mabylon will use the €31.8 million funding to complete Phase Ia/b trials of its lead peanut allergy treatment, MY006, by 2027, aiming to generate safety and preliminary efficacy data.
- The investment will also support the development of early-stage programs, including MY010 for birch-related allergens and MY011 for grass pollen allergies.
"We are very pleased to have closed a CHF 30 million financing agreement in such a challenging global funding environment. This is a strong validation of our approach using human-derived, multi-specific antibodies for the treatment of allergies,“ claims Alcide Barberis, CEO of Mabylon.
